Abstract 203P
Background
The interaction between the immune system and the tumor microenvironment significantly impacts cancer progression and treatment response. Macrophages, with their diverse functional states, play a crucial role in this interplay. Identifying accurate markers for macrophage infiltration is vital for understanding their roles and therapeutic potential.
Methods
Immunai addresses this challenge by developing single cell atlases. Employing state-of-the-art single cell RNA sequencing (scRNA-seq) technologies, Immunai generates comprehensive and high-resolution transcriptomics data from diverse tumor samples, encompassing a wide range of cancer types. The establishment of scRNA-seq data atlases and references enables the identification of distinct macrophage populations within the tumor microenvironment, as well as their heterogeneity and functional states. Utilizing advanced computational algorithms and analytical pipelines, Immunai systematically analyses scRNA-seq datasets to uncover specific molecular signatures associated with macrophage infiltration.
Results
In the presented work, Immunai's approach enabled the discovery of novel macrophage-specific markers that can serve as valuable tools for both basic research and clinical applications. The identified markers offer insights into the dynamic nature of macrophage populations within the tumor microenvironment and provide potential avenues for the development of immunotherapies targeting tumor-associated macrophages. Moreover, these markers hold promise as diagnostic and prognostic indicators, aiding in patient stratification and personalized treatment strategies.
Conclusions
Immunai's approach provides a significant contribution to immuno-oncology and novel therapeutic approaches.
Legal entity responsible for the study
Immunai.
Funding
Immunai.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
136P - Circadian rhythm positioned chronomodulated-SBRT with Cancer associated fibroblast elimination theranostic treatment to harmonize resistant TFG-Beta stromal microenvironment in conjunction with PDL-1 based immunotherapy in disseminated cancers-Concept randomised study.
Presenter: G Lohith
Session: Poster Display
137P - First-in-human results from a Phase I dose-escalation study of VSV-GP (BI 1831169) in patients with advanced solid tumors
Presenter: Stephane Champiat
Session: Poster Display
138P - Generation of frameshift mutated TGF_R2-specific T cells in healthy subjects following administration with cancer vaccine candidate FMPV-1/GM-CSF
Presenter: Else Inderberg
Session: Poster Display
139P - Safety and clinical activity of a novel anti-CCR8 antibody (LM-108) as a single agent or in combination with pembrolizumab in patients with advanced solid tumors: Results of phase 1 study
Presenter: Alexander Starodub
Session: Poster Display
140P - Eliciting mAbs targeting MHC-bound peptides with a novel antibody discovery platform
Presenter: Elli Sandberg
Session: Poster Display
141P - An IgE antibody targeting the melanoma-associated Chondroitin Sulfate Proteoglycan 4
Presenter: Lais Cristina Palhares
Session: Poster Display
142P - Identifying novel immunotherapy targets using machine learning and ex vivo validation
Presenter: Marcellus Augustine
Session: Poster Display
143P - Advancing Cancer Immunotherapy via HLA-G Pathway Modulation with UCB4594
Presenter: Ann WHITE
Session: Poster Display
144P - Discovery of CBO421, a first-in-class Drug Fc-Conjugate (DFC), targeting CD73 in Cancer
Presenter: Simon Döhrmann
Session: Poster Display
145P - An Engineered Ligand-Trap Biologic Targeting the CD47 Signaling Pathway for Cancer Treatment with Superb Efficacy and Safety Profiles
Presenter: ZONG SEAN JUO
Session: Poster Display